User: Guest  Login
Title:

A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.

Document type:
Article; Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Engel-Riedel, Walburga; Lowe, Jamie; Mattson, Paulette; Richard Trout, J; Huhn, Richard D; Gargano, Michele; Patchen, Myra L; Walsh, Richard; Trinh, My My; Dupuis, Mariève; Schneller, Folker
Abstract:
BACKGROUND: BTH1677, a beta-glucan pathogen-associated molecular pattern molecule, drives an anti-cancer immune response in combination with oncology antibody therapies. This phase II study explored the efficacy, pharmacokinetics (PK), and safety of BTH1677 combined with bevacizumab/carboplatin/paclitaxel in patients with untreated advanced non-small cell lung cancer (NSCLC). METHODS: Patients were randomized to the BTH1677 arm (N = 61; intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab...     »
Journal title abbreviation:
J Immunother Cancer
Year:
2018
Journal volume:
6
Journal issue:
1
Fulltext / DOI:
doi:10.1186/s40425-018-0324-z
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/29486797
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX